Source:http://linkedlifedata.com/resource/pubmed/id/11042650
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
7
|
| pubmed:dateCreated |
2000-11-30
|
| pubmed:abstractText |
To evaluate the efficacy and toxicity of two different etoposide (VP-16) dosages (30 or 45 mg/kg) in combination with busulfan/cyclophosphamide as conditioning therapy followed by stem cell transplantation in acute myeloid leukemia (AML), 90 patients with AML received either 30 mg/kg (n = 60) or 45 mg/kg (n = 30) etoposide in combination with busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg). The stem cell source was allogeneic related bone marrow (BM) (n = 53), allogeneic unrelated BM (n = 5), allogeneic unrelated peripheral blood (PBSC) (n = 2), syngeneic BM (n = 2), autologous BM purged (n = 9) or unpurged (n = 9), autologous PBSC (n = 10). Fifty-six patients (62%) were in first CR, 26 (29%) were > first CR, and eight (9%) were transplanted in relapse. Principal toxicities in both groups were mucositis and hepatotoxicity. Forty-five mg/kg etoposide resulted in greater hepatic toxicity (P = 0.03), and a higher incidence of VOD (23 vs 12%, P = 0.04) and acute GVHD grade III/IV (13 vs 5%, NS). The treatment-related mortality was 17% in the 30 mg/kg group and 33% in the 45 mg/kg group, mainly due to infections, intestinal pneumonia and GVHD. Hematological recovery of leukocytes 1/nl was comparable in both groups (17 vs 16 days). After a median follow-up of 16 months 19% in the 30 mg/kg group and 23% in the 45 mg/kg group relapsed. In patients who had undergone allogeneic related bone marrow transplantation in first CR no relapses occurred after a median follow-up of 3 years. For all patients the 3-year estimated disease-free survival was 62% in the 30 mg/kg group and 40% in the 45 mg/kg group (P = 0.03). For patients in first CR who underwent allogeneic related stem cell transplantation the 3 year disease-free survivals were 80% and 66%, respectively (P = 0.4). We conclude that etoposide 30 mg/kg or 45 mg/kg in combination with busulfan/cyclophosphamide is a highly active regimen for bone marrow transplantation of patients with AML with a low relapse rate. However, conditioning with 30 mg/kg rather than 45 mg/kg etoposide resulted in less toxicity and a better overall survival due to a lower transplant-related mortality. Bone Marrow Transplantation (2000) 26, 711-716.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
0268-3369
|
| pubmed:author |
pubmed-author:BraumannDD,
pubmed-author:ColbergHH,
pubmed-author:ErttmannRR,
pubmed-author:FiedlerWW,
pubmed-author:FinkensteinFF,
pubmed-author:HolsteinKK,
pubmed-author:KabischHH,
pubmed-author:KrögerNN,
pubmed-author:KrügerWW,
pubmed-author:KuseRR,
pubmed-author:MayerUU,
pubmed-author:MetznerBB,
pubmed-author:RengeiBB,
pubmed-author:SonnenRR,
pubmed-author:SonnenbergSS,
pubmed-author:StuteNN,
pubmed-author:ZabelinaTT,
pubmed-author:ZanderA RAR,
pubmed-author:del ValleFF
|
| pubmed:issnType |
Print
|
| pubmed:volume |
26
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
711-6
|
| pubmed:dateRevised |
2006-4-24
|
| pubmed:meshHeading |
pubmed-meshheading:11042650-Acute Disease,
pubmed-meshheading:11042650-Adolescent,
pubmed-meshheading:11042650-Adult,
pubmed-meshheading:11042650-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11042650-Blood Platelets,
pubmed-meshheading:11042650-Busulfan,
pubmed-meshheading:11042650-Child,
pubmed-meshheading:11042650-Child, Preschool,
pubmed-meshheading:11042650-Cyclophosphamide,
pubmed-meshheading:11042650-Disease-Free Survival,
pubmed-meshheading:11042650-Dose-Response Relationship, Drug,
pubmed-meshheading:11042650-Drug Evaluation,
pubmed-meshheading:11042650-Etoposide,
pubmed-meshheading:11042650-Female,
pubmed-meshheading:11042650-Follow-Up Studies,
pubmed-meshheading:11042650-Graft Survival,
pubmed-meshheading:11042650-Graft vs Host Disease,
pubmed-meshheading:11042650-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:11042650-Humans,
pubmed-meshheading:11042650-Infant,
pubmed-meshheading:11042650-Leukemia, Myeloid,
pubmed-meshheading:11042650-Leukocytes,
pubmed-meshheading:11042650-Male,
pubmed-meshheading:11042650-Middle Aged,
pubmed-meshheading:11042650-Recurrence,
pubmed-meshheading:11042650-Survival Rate,
pubmed-meshheading:11042650-Transplantation Conditioning,
pubmed-meshheading:11042650-Treatment Outcome
|
| pubmed:year |
2000
|
| pubmed:articleTitle |
Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
|
| pubmed:affiliation |
Bone Marrow Transplantation, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
|
| pubmed:publicationType |
Journal Article
|